Financhill
Sell
43

KRRO Quote, Financials, Valuation and Earnings

Last price:
$13.30
Seasonality move :
2.49%
Day range:
$12.52 - $13.88
52-week range:
$10.29 - $98.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.88x
Volume:
104.5K
Avg. volume:
171.5K
1-year change:
-60.47%
Market cap:
$122.9M
Revenue:
$2.3M
EPS (TTM):
-$9.44

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
KRRO
Korro Bio
$406.9K -$2.60 -82.08% -6.79% $110.37
AIM
AIM ImmunoTech
-- -$0.09 -23.08% -53.85% $4.50
CVM
CEL-SCI
-- -- -- -- $8.00
IGC
IGC Pharma
$326K -$0.03 3.39% -50% $3.88
NBY
NovaBay Pharmaceuticals
$3M -$0.88 14.03% -95.43% $0.85
PLX
Protalix BioTherapeutics
$13.5M -- 0.09% -- $14.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
KRRO
Korro Bio
$13.09 $110.37 $122.9M -- $0.00 0% --
AIM
AIM ImmunoTech
$0.04 $4.50 $2.8M -- $0.00 0% 13.27x
CVM
CEL-SCI
$2.52 $8.00 $7.6M -- $0.00 0% --
IGC
IGC Pharma
$0.31 $3.88 $24.5M -- $0.00 0% 18.48x
NBY
NovaBay Pharmaceuticals
$0.63 $0.85 $3.6M -- $0.00 0% 0.16x
PLX
Protalix BioTherapeutics
$1.50 $14.00 $119.4M 37.50x $0.00 0% 2.10x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
KRRO
Korro Bio
-- -0.086 -- 9.07x
AIM
AIM ImmunoTech
48.41% 0.745 17.25% 0.71x
CVM
CEL-SCI
-- -0.752 -- --
IGC
IGC Pharma
2.1% 0.356 0.51% 0.21x
NBY
NovaBay Pharmaceuticals
4.54% -0.044 1.51% 0.75x
PLX
Protalix BioTherapeutics
-- -1.225 -- 1.62x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
KRRO
Korro Bio
-- -$25M -- -- -981.18% -$24.6M
AIM
AIM ImmunoTech
$27K -$4.5M -219.06% -256.33% -9994.29% -$3.3M
CVM
CEL-SCI
-- -$6.4M -- -- -- -$4.4M
IGC
IGC Pharma
$104K -$1.9M -114.2% -116.24% -730.74% -$1.4M
NBY
NovaBay Pharmaceuticals
$1.6M -$2.7M -334.47% -461.38% -44% -$1.3M
PLX
Protalix BioTherapeutics
$1.9M -$4.1M 8.88% 10.9% -36.84% -$5.4M

Korro Bio vs. Competitors

  • Which has Higher Returns KRRO or AIM?

    AIM ImmunoTech has a net margin of -917.14% compared to Korro Bio's net margin of -10571.43%. Korro Bio's return on equity of -- beat AIM ImmunoTech's return on equity of -256.33%.

    Company Gross Margin Earnings Per Share Invested Capital
    KRRO
    Korro Bio
    -- -$2.49 $139M
    AIM
    AIM ImmunoTech
    77.14% -$0.06 $5.6M
  • What do Analysts Say About KRRO or AIM?

    Korro Bio has a consensus price target of $110.37, signalling upside risk potential of 677.91%. On the other hand AIM ImmunoTech has an analysts' consensus of $4.50 which suggests that it could grow by 11066.25%. Given that AIM ImmunoTech has higher upside potential than Korro Bio, analysts believe AIM ImmunoTech is more attractive than Korro Bio.

    Company Buy Ratings Hold Ratings Sell Ratings
    KRRO
    Korro Bio
    6 0 0
    AIM
    AIM ImmunoTech
    1 0 0
  • Is KRRO or AIM More Risky?

    Korro Bio has a beta of 2.435, which suggesting that the stock is 143.539% more volatile than S&P 500. In comparison AIM ImmunoTech has a beta of 0.760, suggesting its less volatile than the S&P 500 by 23.953%.

  • Which is a Better Dividend Stock KRRO or AIM?

    Korro Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Korro Bio pays -- of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios KRRO or AIM?

    Korro Bio quarterly revenues are $2.6M, which are larger than AIM ImmunoTech quarterly revenues of $35K. Korro Bio's net income of -$23.4M is lower than AIM ImmunoTech's net income of -$3.7M. Notably, Korro Bio's price-to-earnings ratio is -- while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Korro Bio is -- versus 13.27x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    KRRO
    Korro Bio
    -- -- $2.6M -$23.4M
    AIM
    AIM ImmunoTech
    13.27x -- $35K -$3.7M
  • Which has Higher Returns KRRO or CVM?

    CEL-SCI has a net margin of -917.14% compared to Korro Bio's net margin of --. Korro Bio's return on equity of -- beat CEL-SCI's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    KRRO
    Korro Bio
    -- -$2.49 $139M
    CVM
    CEL-SCI
    -- -$2.40 --
  • What do Analysts Say About KRRO or CVM?

    Korro Bio has a consensus price target of $110.37, signalling upside risk potential of 677.91%. On the other hand CEL-SCI has an analysts' consensus of $8.00 which suggests that it could grow by 9424.76%. Given that CEL-SCI has higher upside potential than Korro Bio, analysts believe CEL-SCI is more attractive than Korro Bio.

    Company Buy Ratings Hold Ratings Sell Ratings
    KRRO
    Korro Bio
    6 0 0
    CVM
    CEL-SCI
    1 0 0
  • Is KRRO or CVM More Risky?

    Korro Bio has a beta of 2.435, which suggesting that the stock is 143.539% more volatile than S&P 500. In comparison CEL-SCI has a beta of 0.299, suggesting its less volatile than the S&P 500 by 70.097%.

  • Which is a Better Dividend Stock KRRO or CVM?

    Korro Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Korro Bio pays -- of its earnings as a dividend. CEL-SCI pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios KRRO or CVM?

    Korro Bio quarterly revenues are $2.6M, which are larger than CEL-SCI quarterly revenues of --. Korro Bio's net income of -$23.4M is lower than CEL-SCI's net income of -$6.6M. Notably, Korro Bio's price-to-earnings ratio is -- while CEL-SCI's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Korro Bio is -- versus -- for CEL-SCI. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    KRRO
    Korro Bio
    -- -- $2.6M -$23.4M
    CVM
    CEL-SCI
    -- -- -- -$6.6M
  • Which has Higher Returns KRRO or IGC?

    IGC Pharma has a net margin of -917.14% compared to Korro Bio's net margin of -711.67%. Korro Bio's return on equity of -- beat IGC Pharma's return on equity of -116.24%.

    Company Gross Margin Earnings Per Share Invested Capital
    KRRO
    Korro Bio
    -- -$2.49 $139M
    IGC
    IGC Pharma
    40.47% -$0.02 $6.4M
  • What do Analysts Say About KRRO or IGC?

    Korro Bio has a consensus price target of $110.37, signalling upside risk potential of 677.91%. On the other hand IGC Pharma has an analysts' consensus of $3.88 which suggests that it could grow by 1162.22%. Given that IGC Pharma has higher upside potential than Korro Bio, analysts believe IGC Pharma is more attractive than Korro Bio.

    Company Buy Ratings Hold Ratings Sell Ratings
    KRRO
    Korro Bio
    6 0 0
    IGC
    IGC Pharma
    2 0 0
  • Is KRRO or IGC More Risky?

    Korro Bio has a beta of 2.435, which suggesting that the stock is 143.539% more volatile than S&P 500. In comparison IGC Pharma has a beta of 1.452, suggesting its more volatile than the S&P 500 by 45.212%.

  • Which is a Better Dividend Stock KRRO or IGC?

    Korro Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Korro Bio pays -- of its earnings as a dividend. IGC Pharma pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios KRRO or IGC?

    Korro Bio quarterly revenues are $2.6M, which are larger than IGC Pharma quarterly revenues of $257K. Korro Bio's net income of -$23.4M is lower than IGC Pharma's net income of -$1.8M. Notably, Korro Bio's price-to-earnings ratio is -- while IGC Pharma's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Korro Bio is -- versus 18.48x for IGC Pharma. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    KRRO
    Korro Bio
    -- -- $2.6M -$23.4M
    IGC
    IGC Pharma
    18.48x -- $257K -$1.8M
  • Which has Higher Returns KRRO or NBY?

    NovaBay Pharmaceuticals has a net margin of -917.14% compared to Korro Bio's net margin of -49.65%. Korro Bio's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    KRRO
    Korro Bio
    -- -$2.49 $139M
    NBY
    NovaBay Pharmaceuticals
    65.26% $1.42 $1.1M
  • What do Analysts Say About KRRO or NBY?

    Korro Bio has a consensus price target of $110.37, signalling upside risk potential of 677.91%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 35.98%. Given that Korro Bio has higher upside potential than NovaBay Pharmaceuticals, analysts believe Korro Bio is more attractive than NovaBay Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    KRRO
    Korro Bio
    6 0 0
    NBY
    NovaBay Pharmaceuticals
    1 0 0
  • Is KRRO or NBY More Risky?

    Korro Bio has a beta of 2.435, which suggesting that the stock is 143.539% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.

  • Which is a Better Dividend Stock KRRO or NBY?

    Korro Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Korro Bio pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios KRRO or NBY?

    Korro Bio quarterly revenues are $2.6M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Korro Bio's net income of -$23.4M is lower than NovaBay Pharmaceuticals's net income of $7.7M. Notably, Korro Bio's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Korro Bio is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    KRRO
    Korro Bio
    -- -- $2.6M -$23.4M
    NBY
    NovaBay Pharmaceuticals
    0.16x -- $2.4M $7.7M
  • Which has Higher Returns KRRO or PLX?

    Protalix BioTherapeutics has a net margin of -917.14% compared to Korro Bio's net margin of -35.79%. Korro Bio's return on equity of -- beat Protalix BioTherapeutics's return on equity of 10.9%.

    Company Gross Margin Earnings Per Share Invested Capital
    KRRO
    Korro Bio
    -- -$2.49 $139M
    PLX
    Protalix BioTherapeutics
    19.11% -$0.05 $45.2M
  • What do Analysts Say About KRRO or PLX?

    Korro Bio has a consensus price target of $110.37, signalling upside risk potential of 677.91%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.00 which suggests that it could grow by 833.33%. Given that Protalix BioTherapeutics has higher upside potential than Korro Bio, analysts believe Protalix BioTherapeutics is more attractive than Korro Bio.

    Company Buy Ratings Hold Ratings Sell Ratings
    KRRO
    Korro Bio
    6 0 0
    PLX
    Protalix BioTherapeutics
    0 0 0
  • Is KRRO or PLX More Risky?

    Korro Bio has a beta of 2.435, which suggesting that the stock is 143.539% more volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of -0.227, suggesting its less volatile than the S&P 500 by 122.694%.

  • Which is a Better Dividend Stock KRRO or PLX?

    Korro Bio has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Korro Bio pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios KRRO or PLX?

    Korro Bio quarterly revenues are $2.6M, which are smaller than Protalix BioTherapeutics quarterly revenues of $10.1M. Korro Bio's net income of -$23.4M is lower than Protalix BioTherapeutics's net income of -$3.6M. Notably, Korro Bio's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 37.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Korro Bio is -- versus 2.10x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    KRRO
    Korro Bio
    -- -- $2.6M -$23.4M
    PLX
    Protalix BioTherapeutics
    2.10x 37.50x $10.1M -$3.6M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will Robinhood Stock Keep Going Up?
Will Robinhood Stock Keep Going Up?

Commission-free online brokerage Robinhood (NASDAQ:HOOD) has served up massive gains…

Where Will Hershey Stock Be In 1 Year?
Where Will Hershey Stock Be In 1 Year?

Chocolate stocks used to be the epitome of sleepy stability,…

Where Will KNOT Stock Be In 1 Year?
Where Will KNOT Stock Be In 1 Year?

In the case of KNOT Offshore Partners (KNOP), most headlines…

Stock Ideas

Buy
63
Is NVDA Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 53x

Buy
60
Is MSFT Stock a Buy?

Market Cap: $3.7T
P/E Ratio: 42x

Sell
48
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Alerts

Buy
92
BGL alert for Jul 3

Blue Gold [BGL] is down 20.3% over the past day.

Sell
18
CNC alert for Jul 3

Centene [CNC] is down 1.3% over the past day.

Sell
12
MOH alert for Jul 3

Molina Healthcare [MOH] is up 0.3% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock